Author:
Hirsch Fred R,Bunn Paul A
Reference12 articles.
1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004
2. First-line gefitinib in patients with advanced non-small cell lung cancer harboring somatic EGFR mutations;Sequist;J Clin Oncol,2008
3. Gefitinib vs carboplatin/paclitaxel in clinically selected chemonaive patients with advanced non-small cell lung cancer in Asia (IPASS): Randomized, open-label, phase III study;Mok;J Thorac Oncol,2008
4. Biomarker status correlates with clinical benefit: Phase 2 study of single-agent erlotinib (E) or E intercalated with carboplatin and paclitaxel in an EGFR biomarker selected population;Hirsch;J Thorac Oncol,2008
5. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis;Hirsch;J Clin Oncol,2003
Cited by
165 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献